Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 rozanolixizumab versus placebo in adults with persistent or chronic primary immune thrombocytopenia
NL-OMON49073Phase 3Withdrawn
- Sponsor
- UCB
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rozanolixizumab in immune thrombocytopenia (ITP), sponsored by UCB. Planned start Mar 2020; status: withdrawn.
02
Drugs
rozanolixizumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON49073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49073.